25.09 22:00 | dpa-AFX: GNW-Adhoc: Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results |
31.07 22:00 | dpa-AFX: GNW-Adhoc: Inventiva Reports Preliminary 2024 First-Half Financial Information¹ |
25.07 22:00 | dpa-AFX: GNW-Adhoc: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor |
18.07 08:30 | dpa-AFX: GNW-Adhoc: Inventiva announces a ?20.1 million issuance of royalty certificates |
05.07 22:00 | dpa-AFX: GNW-Adhoc: Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position |
21.06 22:05 | dpa-AFX: GNW-Adhoc: Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 |
21.06 22:00 | dpa-AFX: GNW-Adhoc: Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024 |
30.05 08:30 | dpa-AFX: GNW-Adhoc: Combined General Meeting of June 20, 2024 - Availability of the preparatory documents |
22.05 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces two scientific presentations at the EASL International Liver CongressT 2024 |
21.05 22:00 | dpa-AFX: GNW-Adhoc: Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update |
16.05 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH |
13.05 08:30 | dpa-AFX: GNW-Adhoc: Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor |
03.04 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F |
28.03 08:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the nomination of Andre Turenne as Director |
27.03 21:00 | dpa-AFX: GNW-Adhoc: Inventiva reports its 2023 full-year results |
22.03 21:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results |
18.03 21:00 | dpa-AFX: GNW-Adhoc: Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D |
07.03 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed |
15.02 22:35 | dpa-AFX: GNW-Adhoc: Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 |
24.01 22:15 | dpa-AFX: GNW-Adhoc: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux |
|